Skip to content
ClinCalc Pro
Menu
Calculators Drugs Pathways AI Dx Donate Get the App
BRAF V600 inhibitor (specialist)

Encorafenib

Brand names: Braftovi

Encorafenib is an oral BRAF kinase inhibitor used, in combination regimens, to treat BRAF V600-mutant melanoma and BRAF V600E-mutant colorectal cancer.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

It inhibits mutant BRAF kinase within the MAPK signalling pathway, blocking the constitutive proliferative signalling driven by the BRAF V600 mutation.

Prescribing in practice

  • It must be used only in tumours with a confirmed BRAF V600 mutation and is given in defined combinations (for example with a MEK inhibitor or with cetuximab) to improve efficacy and reduce paradoxical pathway activation.
  • QT prolongation, hepatotoxicity and dermatological effects including new skin lesions can occur and require monitoring.
  • It interacts with CYP3A4 substrates and inhibitors, so concomitant medicines should be reviewed against the SPC.

Monitoring

Monitor liver function, ECG for QT interval, and skin (including for new cutaneous malignancies) before and during treatment.

Counselling the patient

  • Report any new skin lesions, lumps or changing moles to your team.
  • Use sun protection, and tell your team about all other medicines you take.

Evidence & guidelines

Encorafenib combination therapy is supported by trial evidence (COLUMBUS in melanoma and BEACON CRC in colorectal cancer) and appraised by NICE within licensed indications.

Reference: NICE TA562; NICE TA668; ESMO; SmPC; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.

Calculators
Drugs
Pathways